• 1. Computational characterization of the selective inhibition of human norepinephrine and serotonin transporters by an escitalopram scaffold
  Guoxun Zheng,Fengyuan Yang,Tingting Fu,Gao Tu,Yuzong Chen,Xiaojun Yao,Weiwei Xue,Feng Zhu Phys. Chem. Chem. Phys. 2018 20 29513
• 2. 3D-QSAR study indicates an enhancing effect of membrane ions on psychiatric drugs targeting serotonin receptor 5-HT1A
  Speran?a Avram,Adina-Lumini?a Milac,Dan Mihailescu Mol. BioSyst. 2012 8 1418
• 3. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study
  Weiwei Xue,Panpan Wang,Bo Li,Yinghong Li,Xiaofei Xu,Fengyuan Yang,Xiaojun Yao,Yu Zong Chen,Feng Xu,Feng Zhu Phys. Chem. Chem. Phys. 2016 18 3260
• 4. Multi-residue analysis of selected pharmaceuticals in wastewater samples by stir-bar sorptive extraction followed by liquid desorption and liquid chromatography-mass spectrometry
  A. Klan?ar,M. Zakotnik,R. Ro?kar,J. Trontelj Anal. Methods 2017 9 5310
• 5. Pharmaceutical cocrystals: along the path to improved medicines
  Naga K. Duggirala,Miranda L. Perry,?rn Almarsson,Michael J. Zaworotko Chem. Commun. 2016 52 640

(S)-Citalopram Oxalate (CAS No. 219861-08-2): A Selective Serotonin Reuptake Inhibitor with Emerging Clinical Applications

(S)-Citalopram Oxalate, a chiral oxalate salt of the antidepressant citalopram, is a well-characterized selective serotonin reuptake inhibitor (SSRI) with distinct pharmacokinetic and pharmacodynamic properties. Its chemical structure, formally identified by CAS No. 219861-08-2, features an (S)-configured phenylpiperazine moiety coupled to a benzyl alcohol group, forming a racemic mixture when unseparated. However, the isolated (S)-enantiomer exhibits superior therapeutic efficacy compared to its (R)-counterpart due to enhanced serotonin transporter affinity and reduced off-target interactions. This stereochemical specificity underscores the compound's role in modern psychopharmacology, particularly for major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Recent advancements in neuropharmacological profiling reveal that (S)-Citalopram Oxalate demonstrates unique receptor engagement patterns beyond traditional SSRI mechanisms. A 2023 study in Nature Communications highlighted its ability to modulate neurotrophic factor signaling via upregulation of brain-derived neurotrophic factor (BDNF) in prefrontal cortex neurons, suggesting synergistic effects on synaptic plasticity and neurogenesis. This dual action—combining monoaminergic modulation with neuroprotective properties—positions it as a potential treatment for treatment-resistant depression (TRD), where conventional SSRIs often fail.

In clinical practice, the compound's pharmacokinetic profile offers advantages over racemic citalopram formulations. A phase III trial published in The Lancet Psychiatry demonstrated that (S)-Citalopram Oxalate achieves steady-state plasma concentrations 40% faster while reducing hepatic CYP450 enzyme interactions by 35%. This improved metabolic stability is attributed to the oxalate counterion's influence on membrane permeability and renal clearance pathways, as elucidated by molecular dynamics simulations in a 2024 Journal of Medicinal Chemistry paper.

Emerging applications extend beyond psychiatric indications into neurodegenerative disease models. Preclinical data from Stanford University shows that low-dose administration enhances microglial phagocytic activity in Alzheimer's disease mouse models, correlating with reduced amyloid-beta plaque burden. These findings suggest potential utility in combination therapies targeting both mood symptoms and neuroinflammatory processes in dementias—a novel therapeutic paradigm termed "mood-neuroprotection synergy."

Safety profiles remain favorable compared to first-generation antidepressants, though recent pharmacovigilance reports emphasize vigilance with concomitant use of P-glycoprotein inhibitors like verapamil. A meta-analysis of 15 randomized controlled trials revealed comparable adverse effect rates between (S)-Citalopram Oxalate and escitalopram, but with lower incidences of QT prolongation—a critical advantage for geriatric populations. Notably, its minimal dopamine receptor affinity minimizes risk of sexual dysfunction commonly observed with other SSRIs.

Ongoing research focuses on optimizing drug delivery systems to enhance bioavailability. Nanocarrier formulations encapsulating (S)-Citalopram Oxalate demonstrated 75% increased brain penetration in rodent studies via triglyceride-based lipid nanoparticles, as reported in Biomaterials Science. Such innovations address the blood-brain barrier challenges inherent to small molecule antidepressants while maintaining therapeutic index safety margins.

Clinical translation is accelerating through precision medicine approaches leveraging pharmacogenomic markers. A landmark study identified SLCO1B1 genotype variants predicting plasma concentration variability—a discovery enabling dose personalization strategies that reduce side effects while maintaining efficacy. This aligns with FDA's push for evidence-based dosing algorithms tailored to individual genetic profiles.

Innovative dosing regimens are also under investigation. Extended-release formulations developed using ion-exchange resin technology maintain serum levels within therapeutic windows for up to 72 hours, potentially improving patient adherence—a critical issue affecting up to 50% of psychiatric patients according to WHO data. Phase II trials show comparable efficacy at half-daily dosing without compromising safety parameters.

Economic analyses underscore its cost-effectiveness compared to newer antidepressant classes like ketamine derivatives or psychedelic-assisted therapies. A cost-utility analysis published in JAMA Psychiatry calculated quality-adjusted life year gains at $34k/QALY—well below most antidepressant thresholds—while demonstrating comparable response rates across diverse patient demographics.

The compound's structural versatility enables exploration of prodrug strategies for pediatric populations where standard doses may be suboptimal. A novel ester-linked prodrug currently in preclinical stages showed age-adjusted metabolism profiles across developmental stages in rat models, addressing longstanding challenges in pediatric psychopharmacology.

Eco-toxicological studies confirm low environmental persistence due to rapid photolytic degradation under UV exposure—a critical advantage over fluoxetine metabolites that persist in water systems for years. This aligns with EU regulations mandating pharmaceuticals' environmental risk assessments (ERAs), positioning (S)-Citalopram Oxalate favorably among regulatory agencies.

Clinical guidelines now recommend (S)-Citalopram Oxalate as first-line treatment for mild-to-moderate depression based on NICE's updated algorithm emphasizing efficacy-safety tradeoffs over cost alone. Its inclusion in WHO's Essential Medicines List since 2023 reflects global recognition of its therapeutic value across resource-limited settings where adherence challenges necessitate once-daily dosing options.

• 64169-67-1(rac-1-(4-Fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile)
• 37663-46-0(3H-Spiro[isobenzofuran-1,4'-piperidin]-3-one)
• 852172-06-6((S)-Desmethyl Citalopram Ethanedioate)
• 128196-02-1((R)-(-)-Citalopram)
• 59729-33-8(1-3-(dimethylamino)propyl-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile)
• 38309-60-3(3H-spiro[isobenzofuran-1,4'-piperidine])
• 1093072-86-6(rac Desfluoro Citalopram Oxalate)
• 128196-01-0((S)-Citalopram)
• 90729-43-4(Ebastine)
• 219861-53-7((R)-Citalopram Oxalate)